Literature DB >> 26918780

Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible.

Philip V Kaye1, Mohammad Ilyas1, Irshad Soomro1, Syeda A Haider1, Gurprit Atwal2, Sindhu Menon2, Shafiq Gill3, Cathy Richards4, Rebecca Harrison4, Kevin West4, Krish Ragunath1.   

Abstract

AIMS: p53 immunostaining in Barrett's oesophagus (BO) has been shown to be predictive of progression, but data regarding its generalizability to routine practice are lacking. This study compared the reliability of p53 and dysplasia interpretation and grading. METHODS AND
RESULTS: Seventy-two cases encompassing the full spectrum of BO were circulated to 10 pathologists from four institutions after a brief training session in p53 interpretation. Each pathologist classified cases on haematoxylin and eosin (H&E) alone using the Vienna classification and assessed the p53 staining using a qualitative system. Agreement was assessed using kappa statistics. For the four-tier Vienna system, the average unweighted kappa was 0.30. Weighted kappa values varied from 0.27 to 0.69 with an average of 0.47. When grouped into definite dysplasia versus no definite dysplasia the average kappa was 0.55, but the kappa for low-grade dysplasia (LGD) versus high-grade dysplasia (HGD) was only 0.31. For p53, using the three recognized patterns, the unweighted kappa was 0.6 (confidence interval 0.58-0.63). When cases were evaluated with both H&E and p53 the average kappa was 0.61 for definite dysplasia versus the rest.
CONCLUSIONS: p53 immunohistochemistry interpretation is more reliable than dysplasia diagnosis, even with limited training. As it is predictive of prognosis and improves diagnostic reproducibility, it is suitable for routine use by pathologists as an adjunct to dysplasia diagnosis. The distinction of LGD versus HGD was poor. This study supports simplifying dysplasia diagnosis into 'present', 'indefinite' or 'absent', and the use of p53 as an ancillary marker in difficult cases. This should help to prevent overdiagnosis of dysplasia and inappropriate treatment.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Barrett's oesophagus; dysplasia; interobserver agreement; kappa; p53 protein

Mesh:

Substances:

Year:  2016        PMID: 26918780     DOI: 10.1111/his.12956

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

1.  p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.

Authors:  Mamoun Younes; Keith Brown; Gregory Y Lauwers; Gulchin Ergun; Frank Meriano; A Carl Schmulen; Alberto Barroso; Atilla Ertan
Journal:  Histopathology       Date:  2017-04-11       Impact factor: 5.087

2.  Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.

Authors:  Matthew D Stachler; Nicholas D Camarda; Christopher Deitrick; Anthony Kim; Agoston T Agoston; Robert D Odze; Jason L Hornick; Anwesha Nag; Aaron R Thorner; Matthew Ducar; Amy Noffsinger; Richard H Lash; Mark Redston; Scott L Carter; Jon M Davison; Adam J Bass
Journal:  Gastroenterology       Date:  2018-03-31       Impact factor: 22.682

Review 3.  Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.

Authors:  Melissa Schmidt; Richard J Hackett; Ann-Marie Baker; Stuart A C McDonald; Michael Quante; Trevor A Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-02       Impact factor: 46.802

4.  Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.

Authors:  Fiebo J C Ten Kate; Lucia Suzuki; Lambert C J Dorssers; Winand N M Dinjens; David T W Jones; Daan Nieboer; Michael Doukas; J Jan B Van Lanschot; Bas P L Wijnhoven; Leendert H J Looijenga; Katharina Biermann
Journal:  Oncotarget       Date:  2017-10-24

5.  Columnar Metaplasia in Three Types of Surgical Mouse Models of Esophageal Reflux.

Authors:  Fabio Terabe; Susumu Aikou; Junko Aida; Nobutake Yamamichi; Michio Kaminishi; Kaiyo Takubo; Yasuyuki Seto; Sachiyo Nomura
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-04-04

6.  The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study.

Authors:  Richard Phillips; Wladyslaw Januszewicz; Nastazja D Pilonis; Maria O'Donovan; Tarek Sawas; David A Katzka; Rebecca C Fitzgerald; Massimiliano di Pietro
Journal:  Gastrointest Endosc       Date:  2021-02-04       Impact factor: 9.427

Review 7.  Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma.

Authors:  Eleanor M Gregson; Jan Bornschein; Rebecca C Fitzgerald
Journal:  Br J Cancer       Date:  2016-07-21       Impact factor: 7.640

Review 8.  Recent advances in understanding and preventing oesophageal cancer.

Authors:  James Franklin; Janusz Jankowski
Journal:  F1000Res       Date:  2020-04-21

Review 9.  Pterygium-The Good, the Bad, and the Ugly.

Authors:  Sara I Van Acker; Bert Van den Bogerd; Michel Haagdorens; Vasiliki Siozopoulou; Sorcha Ní Dhubhghaill; Isabel Pintelon; Carina Koppen
Journal:  Cells       Date:  2021-06-22       Impact factor: 6.600

Review 10.  Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.

Authors:  Ksenia S Maslyonkina; Alexandra K Konyukova; Darya Y Alexeeva; Mikhail Y Sinelnikov; Liudmila M Mikhaleva
Journal:  Cancer Med       Date:  2021-12-06       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.